A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Multiple sclerosis (MS), the main central nervous system autoimmune disorder, is the first cause of non-traumatic disability in young adults and has thus significant individual consequences with elevated public health cost. It commonly starts during the third and fourth decades. Over the last twenty years, several disease-modifying therapies with variable benefit/risk profiles have been introduced leading to dramatic changes in the prognosis of MS.
First, several moderately effective therapies , with good safety profile, have allowed to decrease the frequency of relapses along with a possible, albeit limited, effect on medium- and long-term disability.
More recently highly effective therapies (HET), with immunosuppressive properties, have dramatically reduced clinical and MRI disease activity and significantly improved patient's prognosis.
Anti-CD20 therapies (B-cells depleting therapies, given either intravenous or subcutaneous), one of the main HET, have demonstrated higher efficacy than platform therapies in several phase 3 randomized clinical trials and their use within the very first years of the disease seems to be associated with improved long-term outcomes.
Taking all of this into account, the investigators hypothesize that RRMS patients who experience a de-escalation from anti-CD20 therapies to platform therapies after 40 years will not experience disease activity accrual and disability worsening.

Start Date01 Sep 2025

Sponsor / Collaborator

University Hospital of Montpellier

NCT05344469

/ RecruitingNot Applicable

A Non-interventional Study Evaluating Injectable Treatments (Ofatumumab, Glatiramer Acetate and Interferon β1) and Oral Treatments (Teriflunomide, Dimethyl Fumarate and Diroximel Fumarate) in Patients With Relapsing Multiple Sclerosis [AIOLOS]

This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany.
Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to four years. Additionally, medical history of participants will be collected including disease duration, laboratory values, EDSS, MRI parameters and relapses.

Start Date10 May 2022

Sponsor / Collaborator

Novartis Pharmaceuticals Corp.

NCT05688436

/ Active, not recruitingNot Applicable

Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

In this study, researchers will learn more about the effects of diroximel fumarate (DRF), also known as VUMERITY®, when taken during pregnancy in people with multiple sclerosis, also known as MS. In MS, the immune system attacks the nerves in the brain and spinal cord. The affected areas are called lesions. The damage makes it difficult for the brain and spinal cord to function and send messages throughout the body. MS can be a progressive disease, which means it may get worse over time. In relapsing forms of MS (RMS), new symptoms may happen, and existing symptoms may get better or worse over time. DRF is an approved drug that is used to treat people with RMS.
This is known as an "observational" study, which collects health information about study participants without changing their medical care. The main goal of this study is to collect birth and health information from 3 groups of participants and their babies. These groups are:
* Those who took DRF during their pregnancy
* Those who took disease-modifying therapies (DMTs) for RMS during their pregnancy, but not DRF. DMTs are drugs that slow how the disease develops over time, not just relieve symptoms.
* Those who did not take any drugs for RMS during their pregnancy
The main question researchers want to learn about in this study is:
• How many participants' babies were born with major congenital malformations (MCMs)? MCMs are problems with how a baby's body forms before birth.
In this study, researchers will measure how often the following outcomes happen and compare them between groups:
* Loss of pregnancy before 20 weeks
* Loss of pregnancy at or after 20 weeks (stillbirth)
* Babies born early (before 37 weeks)
* Babies who are smaller than expected for the stage of pregnancy
* Live births
This study will be done as follows:
* The study includes data in adult women with multiple sclerosis on pregnancies happening between October 29th, 2019 and July 31st, 2030. Information will start being collected when the participant decides to join the study.
* Medical records and clinical notes will be reviewed at the end of the study.
* The study will include information from pregnancy through delivery, and for babies up to 1 year after birth.
* The study is planned to end by 30th April 2031.

Start Date24 Sep 2021

Sponsor / Collaborator

Biogen, Inc.

100 Clinical Results associated with Glatiramer Acetate

100 Translational Medicine associated with Glatiramer Acetate

100 Patents (Medical) associated with Glatiramer Acetate

1,951

Literatures (Medical) associated with Glatiramer Acetate

01 Aug 2026·AMERICAN JOURNAL OF OPHTHALMOLOGY

Risk of Noninfectious Uveitis Associated With Disease-Modifying Therapies for Multiple Sclerosis

Article

Author: Jin, Fangming ; VanderBeek, Brian L ; Cordisco, Anthony J ; Hamedani, Ali G

PURPOSE:

Multiple sclerosis (MS) is associated with an increased risk of non-infectious uveitis (NIU). Whether disease-modifying therapies (DMTs) for MS alter this risk is unknown. Our objective was to determine the comparative risk of NIU after DMT initiation for MS.

DESIGN:

Retrospective clinical cohort study using Optum's de-identified Clinformatics™ Data Mart database, which is comprised of medical claims for patients enrolled in commercial and Medicare Advantage insurance plans from January 1, 2000 - June 30, 2022.

PARTICIPANTS:

Adults with MS, defined by ≥3 diagnosis codes on separate dates, who received ≥1 DMT prescription and had ≥2 years of prior enrollment. Participants could contribute multiple treatment episodes if they switched therapies.

METHODS:

Users of interferons, fumarates, nucleic acid synthesis inhibitors/sphingosine-1-phosphate (S1P) modulators, natalizumab, and anti-CD20 monoclonal antibodies were compared to glatiramer acetate as the reference.

MAIN OUTCOME MEASURES:

Marginal Cox models with robust sandwich covariance matrix estimation were used to calculate adjusted hazard ratios (aHR) for incident NIU, defined as a new ICD code for NIU with a 2^nd confirmatory diagnosis within 120 days. A sensitivity analysis varied this definition to require a new concurrent corticosteroid prescription or ocular injection within 120 days of diagnosis. DMT-specific propensity score models were constructed using multivariable logistic regression with generalized estimating equations (GEE) to calculate overlap weights for adjustment. Participants were censored if they switched treatments, underwent intraocular surgery, or disenrolled.

RESULTS:

Across 48,221 treatment episodes for 43,501 patients, median follow-up ranged from 562-703 days. Compared to glatiramer acetate, the NIU incidence was lower for nucleic acid synthesis inhibitors/S1P modulators (aHR 0.14, 95% CI: 0.07-0.29), fumarates (aHR 0.51, 95% CI: 0.36-0.74), anti-CD20 (aHR 0.66, 95% CI, 0.51-0.85), and interferons (aHR 0.67, 95% CI: 0.50-0.91), but not natalizumab (aHR 0.87, 95% CI: 0.61-1.24). Sensitivity analysis confirmed findings for fumarates (aHR 0.56, 95% CI: 0.38-0.82) and nucleic acid synthesis inhibitors/S1P modulators (aHR 0.16, 95% CI: 0.08-0.33).

CONCLUSIONS:

Certain DMT classes are associated with a protective effect for NIU in MS. If confirmed, these medications could be targeted for personalized MS treatment and potentially repurposed to treat NIU in other patient populations.

01 Jun 2026·Drug Delivery and Translational Research

Intralesional injection of CpG ODNs complexed with glatiramer acetate mitigates systemic cytokine toxicities and synergistically advances checkpoint blockade efficacy

Article

Author: Forrest, Marcus Laird ; Gong, Huan ; Abdelaziz, Moustafa M ; Wu, Xiaoqing ; Griffin, J Daniel ; Groer, Chad E ; Berkland, Cory J ; Xu, Liang ; Li, Mengyue

PD-L1/PD-1 checkpoint inhibitors (CPIs) are mainstream agents for cancer immunotherapy, but the prognosis is unsatisfactory in solid tumor patients lacking preexisting T-cell reactivity. Adjunct therapy strategies including the intratumoral administration of immunostimulants aim to address this limitation. CpG oligodeoxynucleotides (ODNs), TLR9 agonists that can potentiate adaptive immunity, have been widely investigated to tackle PD-L1/PD-1 resistance, but clinical success has been hindered by inconsistent efficacy and immune-related toxicities caused by systemic exposure. Here, we utilized glatiramer acetate (GA), the FDA-approved, lysine-rich polypeptides to complex CpG into polycationic nanoparticles (R4B) and investigated the safety and antitumor efficacy of CpG ODNs in the murine CT26 colorectal carcinoma model. In a maximum tolerated dose study, repetitive R4B treatment displayed comparable antitumor efficacy to CpG alone treatment within a dose range from 15 µg to 150 µg while significantly attenuating systemic proinflammatory cytokine IL-6 release. A pharmacokinetic and biodistribution analysis confirmed that R4B localized and gradually released CpG around the lesions within 96 h while 'naked' CpG quickly diffused from the injection site. Genome-wide transcriptome analysis validated that R4B treatment activated prominent TLR9-driven immune system responses in both lesions and spleens. In a CT26 multiple tumor model, intratumoral administration of R4B generated systemic immune efficacy, evidenced by an abscopal effect on untreated tumors. Notably, R4B treatment accomplished these effects with mitigated systemic proinflammatory cytokines when compared with CpG alone. We further discovered that combining R4B with anti-PD-1 treatment led to the most pronounced effects on tumor growth and longest benefits to survival time. Our investigation into possible mechanisms underlying this phenomenon included increased recruitment of cytotoxic CD8⁺ T cells and natural killer (NK) cells to the tumor microenvironments and the reversal of PD-L1/PD-1 axis inhibition. In summary, these results warrant further investigation for safely improving clinical responses in CPI-resistant solid tumor patients with localized CpG ODN therapy.

01 Jun 2026·CLINICAL PHARMACOLOGY & THERAPEUTICS

Association of Neurodevelopmental Disorders and Congenital Anomalies With Prenatal Multiple Sclerosis Treatment—Real‐World Historical Cohort Study

Article

Author: Gronich, Naomi ; Stein, Nili ; Yahav, Amir ; Rosh, Bar ; Levi, Ofek

There is a paucity of data regarding the effects of prenatal disease‐modifying therapies (DMTs) for multiple sclerosis (MS), on congenital anomalies in the offspring. Moreover, data on the association with neurodevelopmental disorders are lacking. This is an historical cohort study, within the Israeli Clalit Health Services database (2005–2024) that included all children, born to mothers carrying a diagnosis of MS. Mothers' demographic and clinical characteristics were used to account for potential confounders. A marginal model used for the association between prenatal dispensed DMTs and neurodevelopmental disorders. A log‐binomial regression model used to estimate relative risks (RR), 95% CI for the association between exposure and major congenital anomalies (MCAs). The cohort included 1374 children: 484 exposed prenatally to DMTs (237, 85, 56, 49, 25, 32 exposed to interferon‐β, glatiramer, monoclonal antibodies, fumarates, sphingosine‐1‐phosphate receptor (S1PR) modulators, or a combination of therapies, respectively). In a mean follow‐up of 7.5 years (maximum 19.8 years), prenatal exposure to DMTs was not associated with significant risk for neurodevelopmental disorders, in univariate and in multivariate models. Within 1252 children with 2 years of follow‐up, 50 (3.9%) children were identified with MCAs. There was higher rate of MCAs among S1PR modulator‐exposed children 2(8%). Due to the small group risk estimates for S1PR modulators had wide CIs, with RR = 2.0 (95% CI 0.51–8.1, P = 0.314); RR = 5.16 (95% CI 1.47–18.2, P = 0.011) in the univariate and sensitivity analysis, respectively. In conclusion, in the current cohort, prenatal exposure to DMTs was not associated with neurodevelopmental disorders. Exposure to S1PR modulators in pregnancy was associated with higher risk for congenital anomalies. Prospective larger studies are warranted.

153

News (Medical) associated with Glatiramer Acetate

29 Apr 2026

·www.fiercepharma.com

With Austedo at helm, Teva's impressive innovative drug sales signal company's successful metamorphosis

Over the first three months of the year, Teva generated revenues of roughly $4 billion, representing a 2% increase in U.S. currencies and a 3% decrease in local currency terms. While Teva Pharmaceutical’s multiyear growth streak under CEO Richard Francis showed signs of leveling off, the company still topped Wall Street estimates in 2026’s first quarter, buoyed by the impressive performance of branded drugs like Austedo, Uzedy and Ajovy. Meanwhile, with some seven additional potential readouts or regulatory decisions stemming from its innovative pipeline this year, it’s not just about beating those industry watcher estimates, “but how we beat,” Francis said in an interview with Fierce. Francis argued that the performance and pipeline catalysts lined up in the first quarter offer a signal that Teva’s pivot from pure generic specialist to fully-fledged biopharma “has really happened”—and at least one team of analysts may agree.Umer Raffat’s group at Evercore ISI wrote in a note to clients that attention is increasingly turning to Teva’s R&D darlings as the company enters a “very active phase.” Over the first three months of the year, Teva generated revenues of roughly $4 billion, representing a 2% increase in U.S. currencies and a 3% decrease in local currency terms, according to an April 29 press release. The company has been on an impressive growth track since shortly after Francis’ arrival in 2023, although the company has said it expects that rate of momentum to slow for a bit in 2026. Teva’s overall performance topped Wall Street estimates for Q1, according to Bloomberg News, which also pointed out that the company’s Huntington’s disease and tardive dyskinesia drug Austedo, its migraine med Ajovy and the multiple sclerosis therapy Copaxone bested the Street's sales predictions for the period. The company’s stock was trading up around 9.5% on Wednesday afternoon. Breaking down the numbers, Austedo brought home $578 million over the three-month stretch, representing 41% growth in local currencies, while Ajovy grew a similar impressive 35% year-over-year to hit $196 million in Q1. The main hit Teva logged for the quarter was a generics sales decline—clocking in at 16%—which the company has been telegraphing for some time as sales of its Revlimid generic falter amid increased competition in the U.S. Elsewhere, the company’s long-acting formulation of risperidone, Uzedy, reached $63 million for the quarter, which Teva said marks the “fastest-growing long-acting injectable” in the space. In a bid to further gird its pipeline, Teva is picking up a Tourette syndrome asset that could be up for an approval decision next year via its $700 million acquisition of Emalex Biosciences, also announced Wednesday. The deal revolves primarily around ecopipam, a dopamine D1 receptor antagonist that Teva plans to file with the FDA in the second half of the year. Francis said Emalex’s asset “falls into the criteria and the strategy we laid out,” noting that ecopipam is de-risked and has passed its phase 3. Moreover, Tourette syndrome represents a significant unmet medical need. More than 100,000 children suffer from the condition in the U.S., but just around half of them are on therapy, with a much smaller proportion staying on therapy after a year, Francis said.Further, there could be an overlap between a Tourette asset and Teva’s existing familiarity with movement disorder and psychiatric spaces, thanks to Austedo and Uzedy, the CEO pointed out.Speaking of Uzedy, Francis noted the drug has “almost doubled the size of the risperidone long-acting market,” and it has also given Teva further confidence that it can continue to unlock the schizophrenia space with its long-acting formulation of olanzapine, which the FDA accepted for review in February and is expected to weigh in on late this year. And while Uzedy launched into a crowded arena, there “is no long-acting market for olanzapine,” Francis pointed out, giving Teva a fresh chance to lay the commercial foundation for its launch. As for Teva’s dealmaking strategy going forward after Emalex, Francis reiterated that the company is “agnostic as to where things come from, internal or external,” but noted that “we like things to fall into our neuroscience capability, and so that’s what we predominantly focus on.” At the same time, Francis stressed that Teva “will not do something that we think is the wrong price or the wrong level of risk.”

AcquisitionPhase 3Biosimilar

29 Apr 2026

·www.biospace.com

Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution

For an accessible version of this Press Release, please visit Q1 2026 revenues of ~$4.0 billion increased by 2% in U.S. dollars year-over-year (YoY), and decreased by 3% in local currency terms (LC). Excluding the Japan business venture (BV) results, revenues decreased by 1% in LC. These strong first quarter results were driven by our innovative portfolio growth and disciplined execution, even with lower revenues from lenalidomide capsules (the generic version of Revlimid ® ) due to increased generic competition in the U.S. Key Innovative brands continued to drive growth and provide value for patients, while transforming Teva's portfolio mix and financial profile: AUSTEDO ® continued to show strong growth, with global revenues of $578 million, growing 41% YoY in LC. AJOVY ® global revenues of $196 million, increased by 35% YoY in LC. UZEDY ® revenues of $63 million, increased by 62% YoY in LC. Fastest growing long-acting injectable (LAI) 1 has nearly doubled the overall risperidone market since launch. Collectively these brands’ revenues grew by 41% YoY in LC. Generics revenues are lower in Q1 2026 vs. Q1 2025, mainly due to lenalidomide capsules (the generic version of Revlimid ® ) impact; Biosimilar portfolio increasingly important contributor to performance and on track to deliver $800 in revenues by 2027: Global generics revenues decreased by 16% YoY in LC, mainly due to lower revenues from generic products in the U.S., primarily lenalidomide capsules (the generic version of Revlimid ® ) due to increased generic competition in the U.S., and the divestment of the business venture in Japan in Q1 2025. Biosimilar PONLIMSI™, received FDA-approval across all indications of the reference product, Prolia ® (denosumab) and our biosimilar candidate to Xolair ® (omalizumab) was accepted for review by U.S. FDA and EU EMA ( link ). Innovative late-stage pipeline continued to drive transformation : Four innovative product submissions targeted over the next 5 years. duvakitug (anti-TL1A) Phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis (UC) and Crohn’s disease (CD); Phase 2b induction data have been accepted for future publication in a leading journal; Phase 3 enrollment currently on target. olanzapine LAI New Drug Application (NDA) accepted by the FDA in February 2026 for once-monthly treatment of schizophrenia in adults; preparing for the launch of olanzapine LAI in Q4 2026, subject to regulatory approval. EU marketing authorization application (MAA) acceptance expected in Q2 2026. Teva to acquire Emalex Biosciences, adding NDA-Ready, first-in-class therapy to neuroscience pipeline and accelerating Teva’s Pivot to Growth strategy. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals, and is currently anticipated to close by the third quarter of 2026 ( link ). Continuing to transform and modernize our business through Teva Transformation programs – combined with innovative product growth, expected to achieve 30% non-GAAP operating income margin by 2027. On track to deliver ~$700 million of net savings by 2027. Teva’s Board of Directors instructed management to plan for a share repurchase program that may be implemented, subject to meeting applicable legal requirements. Execution will be subject to certain factors, such as market conditions, share price and other opportunities to invest capital for growth in alignment with the Company’s Pivot to Growth strategy, and are subject to the approval by Teva’s Board of Directors. Q1 2026 Highlights: Revenues of $4.0 billion GAAP diluted EPS of $0.31 Non-GAAP diluted EPS of $0.53 Cash flow used in operating activities of $40 million Free cash flow of $188 million 2026 Business Outlook m aintained; u pdated exclusively for Emalex transaction: Revenues of $16.4 - $16.8 billion Non-GAAP operating income of $3.80 – $4.0 billion ($4.55 - $4.8 billion stand-alone), impacted by an expected $700 million IPR&D charge and $75 million to reflect Emalex’s operating expenses and transaction-related expenses. Adjusted EBITDA of $4.23 – $4.53 billion ($5.0 - $5.3 billion stand-alone) Non-GAAP diluted EPS of $1.91 – $2.11 ($2.57 - $2.77 stand-alone) Free cash flow of $2.0 - $2.4 billion ________________ 1 IQVIA Monthly NPA, March 2026 MAT vs PY TEL AVIV, Israel, April 29, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2026. Mr. Richard Francis, Teva's President and CEO , said: "Our first quarter results are driven by strong growth in our key innovative products, continuing to shift Teva’s portfolio mix and support improvement in its financial profile. These results reflect disciplined execution of our Pivot to Growth strategy, and our focus remains unchanged: growing our innovative portfolio, improving margins and advancing key value-unlocking portfolio milestones expected during 2026 and beyond. Mr. Francis added, “In parallel, biosimilars are becoming an increasingly important growth contributor, alongside new product launches in generics, reinforcing the foundational importance of Teva's generic powerhouse. Pivot to Growth Strategy In the first quarter of 2026, we continued to execute on the four key pillars of our “Pivot to Growth” strategy, announced in May 2023: Delivering on our growth engines - Teva’s key innovative brands delivered strong performance. In Q1 2026, AUSTEDO, AJOVY, and UZEDY revenues collectively grew by 41% YoY in LC to $838 million compared to Q1 2025. Based on our 2026 Outlook, these products are expected to generate an annual 4-year compound growth rate of ~38% and comprise ~21% of Teva’s total revenues. Stepping up innovation - We continued to advance our innovative late-stage pipeline. In February 2026, we shared topline results from the maintenance period of our Phase 2b study of duvakitug in UC and CD. The data demonstrated robust, durable efficacy over the course of 44 weeks, and positions duvakitug to potentially be the “best-in-class” anti-TL1A. Phase 3 enrollment is currently on target. Teva’s NDA for olanzapine LAI was accepted by the FDA in February 2026. Teva is preparing for the anticipated launch of olanzapine LAI in Q4 2026, subject to receiving regulatory approval. During the remainder of 2026, Teva expects meaningful data updates on five other key innovative programs, including: emrusolmin in MSA, IL-15 (TEV-‘408) in Celiac disease and vitiligo, DARI (Dual-action Asthma Rescue Inhaler) in asthma, and Anti-PD-1/IL-2 in oncology. Sustaining our generics powerhouse - Recently launched biosimilars, including SELARSDI ® (ustekinumab-aekn) the biosimilar to Stelara ® and EPYSQLI ® (eculizumab-aagh) the biosimilar to Soliris ® , along with the rest of our biosimilar portfolio, showed continued strong growth in the Q1 2026. In March 2026, PONLIMSI (denosumab-adet) has been approved by the FDA as a biosimilar to Prolia ® , and Teva’s applications for a proposed biosimilar candidate to Xolair ® (omalizumab) have been accepted by both the U.S. FDA and the European Medicines Agency (EMA). Focusing our business - We are actively transforming and modernizing our business through Teva Transformation programs. On May 7, 2025, we announced that these programs are expected to generate ~$700 million of net savings through 2027, and expect to realize two-thirds of the targeted savings in 2026. In April 2026, Teva entered into a definitive agreement to acquire Emalex Biosciences, including its lead asset ecopipam. Emalex has completed Phase 3 development of ecopipam for the treatment of Tourette syndrome in a pediatric population. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals, and is currently anticipated to close by the third quarter of 2026 ( link ). F irst Q uarter 2026 Consolidated Results Revenues in the first quarter of 2026 were $3,982 million, an increase of 2% in U.S. dollars, or a decrease of 3% in local currency terms compared to the first quarter of 2025. This decrease in local currency terms was mainly due to lower revenues from generic products, primarily lenalidomide capsules (the generic version of Revlimid ® ) in our U.S. segment as well as the divestment of our business venture in Japan in our International Markets segment, partially offset by higher revenues from our key innovative products, primarily AUSTEDO. Exchange rate movements during the first quarter of 2026, including hedging effects, positively impacted revenues by $219 million, compared to the first quarter of 2025. Gross profit in the first quarter of 2026 was $1,972 million, an increase of 5% compared to $1,877 million in the first quarter of 2025. Gross profit margin was 49.5% in the first quarter of 2026, compared to 48.2% in the first quarter of 2025. Non-GAAP gross profit was $2,108 million in the first quarter of 2026, an increase of 3% compared to $2,054 million in the first quarter of 2025. Non-GAAP gross profit margin was 52.9% in the first quarter of 2026, compared to 52.8% in the first quarter of 2025. The increase in both gross profit margin and non-GAAP gross profit margin was mainly due to higher revenues from AUSTEDO, partially offset by lower revenues from generic products in our United States segment, primarily lenalidomide capsules (the generic version of Revlimid ® ). Research and Development (R&D) expenses, net in the first quarter of 2026, were $222 million, a decrease of 10% compared to $247 million in the first quarter of 2025. Our lower R&D expenses, net in the first quarter of 2026 compared to the first quarter of 2025, were mainly due to a decrease in our generics pipeline and in our late-stage innovative pipeline in neuroscience, partially offset by an increase in immunology projects. Our R&D expenses, net in the first quarter of 2026 and 2025, were also impacted by reimbursements and cost sharing from our strategic partnerships and collaborations entered into in recent years. Selling and Marketing (S&M) expenses in the first quarter of 2026, were $696 million, an increase of 12% compared to the first quarter of 2025. This increase was mainly due to promotional activities related to our key innovative products in our US segment, primarily AUSTEDO, as well as a negative impact from exchange rate fluctuations. General and Administrative (G&A) expenses in the first quarter of 2026 were $304 million, an increase of 2% compared to the first quarter of 2025. Other I ncome (Loss) in the first quarter of 2026 was $9 million, compared to other loss of $5 million in the first quarter of 2025. Operating I ncome in the first quarter of 2026 was $652 million, compared to $519 million in the first quarter of 2025. Operating income as a percentage of revenues was 16.4% in the first quarter of 2026, compared to 13.3% in the first quarter of 2025. This increase was mainly due to lower intangible assets impairments and higher gross profit, partially offset by higher S&M expenses. N on-GAAP operating income in the first quarter of 2026 was $956 million representing a non-GAAP operating margin of 24.0% compared to $946 million representing 24.3%, respectively, in the first quarter of 2025. The decrease in non-GAAP operating margin in the first quarter of 2026 was due to higher S&M expenses as a percentage of revenues, partially offset by higher gross profit margin, as discussed above. Exchange rate movements in the first quarter of 2026, including hedging effects, had a positive impact of $71 million on our operating income and non-GAAP operating income compared to the first quarter of 2025. Financial expenses, net in the first quarter of 2026, were $216 million, mainly comprised of net interest expenses of $201 million. In the first quarter of 2025, financial expenses, net were $225 million, mainly comprised of net interest expenses of $212 million. In the first quarter of 2026, we recognized a tax expense of $67 million, on pre-tax income of $437 million. In the first quarter of 2025, we recognized a tax expense of $74 million, on pre-tax income of $294 million. T ax rate in the first quarter of 2026 was 15.5% compared to a tax rate of 25.1% for the first quarter of 2025. Non-GAAP tax rate in the first quarter of 2026 was 17.5%, same as in the first quarter of 2025. Our tax rate and non-GAAP tax rate in the first quarter of 2026 was mainly affected by the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate, infrequent or non-recurring items, including internal legal entities reorganization. Our tax rate and non-GAAP tax rate in the first quarter of 2025 was mainly affected by the generation of profits in various jurisdictions in which tax rates are different than the Israeli tax rate as well as infrequent or non-recurring items. We expect our annual non-GAAP tax rate for 2026 to be between 20%-23% (16%-19% stand-alone), higher than our non-GAAP tax rate for 2025, which was 15.8%. Net income attributable to Teva and diluted earning s per share in the first quarter of 2026 were $369 million and $0.31, respectively, compared to $214 million and $0.18, respectively, in the first quarter of 2025. This increase was mainly due to higher operating income as discussed above. Non-GAAP net income attributable to Teva and non-GAAP diluted earnings per share in the first quarter of 2026 were $621 million and $0.53, respectively, compared to $602 million and $0.52, respectively, in the first quarter of 2025. Adjusted EBITDA was $1,055 million in the first quarter of 2026, an increase of 1%, compared to $1,041 million in the first quarter of 2025. As of March 31, 2026 and 2025, the fully diluted share count for purposes of calculating our market capitalization was approximately 1,192 million shares and 1,178 million shares, respectively. Non-GAAP information : non-GAAP adjustments in the first quarter of 2026 were $252 million. Non-GAAP net income attributable to Teva and non-GAAP diluted EPS for the first quarter of 2026 were adjusted to exclude the following items: Amortization of purchased intangible assets of $137 million, of which $128 million is included in cost of sales and the remaining $9 million in S&M expenses; Legal settlements and loss contingencies of $72 million; Restructuring expenses of $25 million; Impairment of long-lived assets of $9 million; Contingent consideration expenses of $5 million; Gain on sale of business of $5 million; Equity compensation expenses of $43 million; Financial expenses of $13 million; Other non-GAAP items of $17 million; and Corresponding tax effects and unusual tax items of $65 million. We believe that excluding such items facilitates investors’ understanding of our business including underlying trends, thereby improving the comparability of our business performance results between reporting periods. For a reconciliation of the U.S. GAAP results to the adjusted non-GAAP figures and for additional information, see the tables below and the information included under “Non-GAAP Financial Measures.” Investors should consider non-GAAP financial measures in addition to, and not as replacement for, or superior to, measures of financial performance prepared in accordance with GAAP. Cash flow used in operating activities during the first quarter of 2026 was $40 million compared to $105 million in the first quarter of 2025. The lower cash flow used in operating activities in the first quarter of 2026 was mainly due to favorable timing and mix of sales and collections in our U.S. segment as well as lower payments of interest, partially offset by higher performance incentive payments to employees. During the first quarter of 2026, we generated free cash flow of $188 million, which we define as comprising $40 million in cash flow used in operating activities, $354 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $42 million of proceeds from sale of businesses and long-lived assets, partially offset by $168 million in cash used for capital investments. During the first quarter of 2025, we generated free cash flow of $107 million, which we define as comprising $105 million in cash flow used in operating activities, $322 million in beneficial interest collected in exchange for securitized accounts receivables (under our EU securitization program) and $17 million proceeds from sale of businesses and long-lived assets, partially offset by $127 million in cash used for capital investments. The increase in the first quarter of 2026 resulted mainly from lower cash flow used in operating activities, as discussed above. As of March 31, 2026, our debt was $16,627 million, compared to $16,807 million as of December 31, 2025. This decrease was mainly due to $174 million of exchange rate fluctuations. The portion of total debt classified as short-term as of March 31, 2026 was 16% compared to 11% as of December 31, 2025. Our financial leverage, which is the ratio between our debt and the sum of our debt and equity, was 67% as of March 31, 2026, compared to 68% as of December 31, 2025. Our average debt maturity was approximately 5.4 years as of March 31, 2026, compared to 5.6 years as of December 31, 2025. Segment Results for the First Quarter of 2026 United States Segment In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda is reported as part of the Company’s Other Activities. Prior period amounts have been recast to reflect this change. The following table presents revenues, expenses and profit for our United States segment for the three months ended March 31, 2026 and 2025: Three months ended March 31, 2026 2025 (U.S. $ in millions / % of Segment Revenues) Revenues $ 1,534 100% $ 1,536 100% Cost of sales 496 32.3% 523 34.1% Gross profit 1,038 67.7% 1,013 65.9% R&D expenses 147 9.6% 154 10.1% S&M expenses 298 19.4% 244 15.9% G&A expenses 90 5.9% 95 6.2% Other (4) § 3 § Segment profit* $ 507 33.0% $ 518 33.7% * Segment profit does not include amortization and certain other items. § Represents an amount less than 0.5%. Revenues from our United States segment in the first quarter of 2026 were $1,534 million, flat compared to the first quarter of 2025, mainly due to lower revenues from our generic products, primarily lenalidomide capsules (the generic version of Revlimid ® ), offset by higher revenues from our key innovative products, primarily AUSTEDO. Revenues by Major Products and Activities The following table presents revenues for our United States segment by major products and activities for the three months ended March 31, 2026 and 2025: Three months ended March 31, Percentage Change 2026 2025 2026-2025 (U.S. $ in millions) Generic products (including biosimilars) $ 612 $ 849 (28%) AJOVY ® 87 53 64% AUSTEDO 559 396 41% BENDEKA ® and TREANDA ® 27 36 (26%) COPAXONE ® 62 54 16% UZEDY 63 39 62% Other* 123 109 13% Total $ 1,534 $ 1,536 § *Other revenues in the first quarter of 2026 include the sale of certain product rights. § Represents an amount less than 0.5%. Generic products (including biosimilar products) revenues in our United States segment in the first quarter of 2026 were $612 million, a decrease of 28% compared to the first quarter of 2025. This decrease was mainly driven by lower revenues from lenalidomide capsules (the generic version of Revlimid ® ) due to increased generic competition in the U.S., partially offset by higher revenues from our portfolio of biosimilar products. Among the most significant generic products we sold in the United States in the first quarter of 2026 were Truxima ® (the biosimilar to Rituxan ® ), epinephrine injectable solution (the generic equivalent of EpiPen ® and EpiPen Jr ® ) and SIMLANDI ® (the biosimilar to Humira ® ). In the first quarter of 2026, our total prescriptions were approximately 246 million (based on trailing twelve months), representing 6.3% of total U.S. generic prescriptions, compared to approximately 273 million (based on trailing twelve months), representing 7.1% of total U.S. generic prescriptions in the first quarter of 2025, all according to IQVIA data. AJOVY revenues in our United States segment in the first quarter of 2026 were $87 million, an increase of 64% compared to the first quarter of 2025, mainly due to a reduction in sales allowance. In the first quarter of 2026, AJOVY’s exit market share in the United States in terms of total number of prescriptions was 32.0% out of the subcutaneous injectable anti- CGRP class, compared to 30.2% in the first quarter of 2025. AUSTEDO revenues (which include AUSTEDO XR ® ) in our United States segment in the first quarter of 2026 were $559 million, an increase of 41%, compared to in the first quarter of 2025. This increase was mainly due to growth in volume. AUSTEDO XR (deutetrabenazine) extended-release tablets was approved by the FDA on February 17, 2023 in three doses of 6, 12 and 24 mg, and became commercially available in the U.S. in May 2023. The FDA approved AUSTEDO XR as a one pill, once-daily treatment option in doses of 30, 36, 42, and 48 mg in May 2024 and in doses of 18 mg in July 2024. AUSTEDO XR is a once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’s disease, which is additional to the twice-daily AUSTEDO. AUSTEDO XR is protected by 11 Orange Book patents expiring between 2031 and 2041. UZEDY (risperidone) extended-release injectable suspension revenues in our United States segment in the first quarter of 2026 were $63 million, an increase of 62% compared to the first quarter of 2025, mainly due to growth in volume. BENDEKA and TREANDA combined revenues in our United States segment in the first quarter of 2026 were $27 million, a decrease of 26% compared to the first quarter of 2025, mainly due to competition from alternative therapies, as well as from generic bendamustine products. COPAXONE revenues in our United States segment in the first quarter of 2026 were $62 million, an increase of 16% compared to the first quarter of 2025, mainly due to a reduction in sales allowance, partially offset by lower volumes. COPAXONE continues to face competition from existing alternative therapies, generic versions of COPAXONE, and generic treatments for multiple sclerosis, injectable products, as well as from monoclonal antibodies. United States Gross Profit Gross profit from our United States segment in the first quarter of 2026 was $1,038 million, an increase of 2%, compared to the first quarter of 2025. Gross profit margin for our United States segment in the first quarter of 2026 increased to 67.7%, compared to 65.9% in the first quarter of 2025. This increase was mainly due to higher revenues from AUSTEDO, partially offset by lower revenues from generic products, primarily lenalidomide capsules (the generic version of Revlimid®). United States Profit Profit from our United States segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items. Profit from our United States segment in the first quarter of 2026 was $507 million, a decrease of 2% compared to the first quarter of 2025. This decrease was mainly due to higher S&M expenses, partially offset by higher gross profit, as discussed above. Europe Segment Our Europe segment includes the European Union, the United Kingdom and certain other European countries. The following table presents revenues, expenses and profit for our Europe segment for the three months ended March 31, 2026 and 2025: Three months ended March 31, 2026 2025 (U.S. $ in millions / % of Segment Revenues) Revenues $ 1,340 100% $ 1,194 100% Cost of sales 606 45.2% 536 44.9% Gross profit 734 54.8% 658 55.1% R&D expenses 45 3.4% 60 5.1% S&M expenses 215 16.0% 199 16.7% G&A expenses 73 5.4% 69 5.8% Other § § § § Segment profit* $ 401 29.9% $ 329 27.6% * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5%, as applicable. Revenues from our Europe segment in the first quarter of 2026 were $1,340 million, an increase of 12%, compared to the first quarter of 2025. In local currency terms, revenues decreased by 1% compared to the first quarter of 2025, mainly due to lower revenues from generic products, partially offset by higher revenues from AJOVY. In the first quarter of 2026, revenues were positively impacted by exchange rate fluctuations of $159 million, including hedging effects, compared to the first quarter of 2025. Revenues in the first quarter of 2026 included $10 million from a positive hedging impact, which is included in “Other” in the table below. Revenues in the first quarter of 2025 included $12 million from a negative hedging impact, which is included in “Other” in the table below. Revenues by Major Products and Activities The following table presents revenues for our Europe segment by major products and activities for the three months ended March 31, 2026 and 2025: Three months ended March 31, Percentage Change 2026 2025 2026-2025 (U.S. $ in millions) Generic products (including OTC and biosimilars) $ 1,089 $ 989 10% AJOVY 76 58 31% COPAXONE 40 42 (4%) Respiratory products 59 55 8% Other* 76 50 52% Total $ 1,340 $ 1,194 12% * Other revenues in the first quarter of 2026 and 2025 include the sale of certain product rights. Generic products revenues (including OTC and biosimilar products) in our Europe segment in the first quarter of 2026 were $1,089 million, an increase of 10% compared to the first quarter of 2025. In local currency terms, revenues decreased by 1%, mainly due to lower sales of seasonal OTC products, partially offset by higher revenues from recently launched products. AJOVY revenues in our Europe segment in the first quarter of 2026 were $76 million, an increase of 31% compared to the first quarter of 2025. In local currency terms revenues increased by 17% due to growth in volume. COPAXONE revenues in our Europe segment in the first quarter of 2026 were $40 million, a decrease of 4% compared to the first quarter of 2025. In local currency terms revenues decreased by 14%, mainly due to price reductions and lower volumes resulting from the availability of alternative therapies. Respiratory products revenues in our Europe segment in the first quarter of 2026 were $59 million, an increase of 8% compared to the first quarter of 2025. In local currency terms, revenues decreased by 2%, mainly due to net price reductions and lower volumes. Europe Gross Profit Gross profit from our Europe segment in the first quarter of 2026 was $734 million, an increase of 12% compared to the first quarter of 2025. Gross profit margin for our Europe segment in the first quarter of 2026 decreased to 54.8%, compared to 55.1% in the first quarter of 2025. Europe Profit Profit from our Europe segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items. Profit from our Europe segment in the first quarter of 2026 was $401 million, an increase of 22%, compared to the first quarter of 2025. This increase was mainly due to higher gross profit, as discussed above. International Markets Segment Our International Markets segment includes all countries in which we operate other than the United States and the countries included in our Europe segment. The International Markets segment covers a substantial portion of the global pharmaceutical industry, including more than 35 countries. The countries in our International Markets segment include highly regulated, mainly generic markets, such as Canada and Israel, and branded generics-oriented markets, such as Russia and certain Latin America markets. On March 31, 2025, we divested our Teva-Takeda business venture in Japan, which included generic products and legacy products. Since the establishment of the business venture and until the completion of its sale, Teva held 51% of the outstanding common stock of the business venture. On March 31, 2025, we deconsolidated the business venture from our financial statements. The following table presents revenues, expenses and profit for our International Markets segment for the three months ended March 31, 2026 and 2025: Three months ended March 31, 2026 2025 (U.S. $ in millions / % of Segment Revenues) Revenues $ 524 100% $ 582 100% Cost of sales 280 53.6% 304 52.3% Gross profit 243 46.4% 278 47.7% R&D expenses 22 4.3% 25 4.3% S&M expenses 117 22.3% 118 20.2% G&A expenses 39 7.5% 39 6.7% Other § § (1) § Segment profit* $ 65 12.3% $ 97 16.7% * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million or 0.5%, as applicable. Revenues from our International Markets segment in the first quarter of 2026 were $524 million, a decrease of 10% compared to the first quarter of 2025. In local currency terms, revenues decreased by 19% compared to the first quarter of 2025, mainly due to the divestment of our business venture in Japan. In the first quarter of 2026, revenues were positively impacted by exchange rate fluctuations of $50 million, including hedging effects, compared to the first quarter of 2025. Revenues in the first quarter of 2026 included $1 million from a positive hedging impact, compared to a negative hedging impact of $15 million in the first quarter of 2025, which are included in “Other” in the table below. The following table presents revenues for our International Markets segment by major products and activities for the three months ended March 31, 2026 and 2025: Three months ended March 31, Percentage Change 2026 2025 2026-2025 (U.S. $ in millions) Generic products (including OTC and biosimilars) $ 386 $ 468 (18%) AJOVY 33 28 20% AUSTEDO 19 15 30% COPAXONE 6 10 (43%) Other* 79 61 30% Total $ 524 $ 582 (10%) *Other revenues in the first quarter of 2026 and 2025 include the sale of certain product rights. Generic products revenues (including OTC and biosimilar products) in our International Markets segment in the first quarter of 2026 were $386 million, a decrease of 18% compared to the first quarter of 2025. In local currency terms, revenues decreased by 23%, mainly due to the divestment of our business venture in Japan. AJOVY revenues in our International Markets segment in the first quarter of 2026 were $33 million, an increase of 20%, compared to $28 million in the first quarter of 2025. In local currency terms, revenues increased by 15%, mainly due to growth in existing markets in which AJOVY was launched. AJOVY was launched in certain markets in our International Markets segment, including in Canada, Japan, Australia, Israel, South Korea, Brazil and others. In April 2026, we announced a strategic partnership for the marketing and distribution of AJOVY in China with Neurogen (Zhuhai) Pharmaceutical Company Ltd. AUSTEDO revenues in our International Markets segment in the first quarter of 2026 were $19 million an increase of 30%, compared to the first quarter of 2025. In local currency terms, revenues increased by 22% compared to the first quarter of 2025. AUSTEDO was launched in China and Israel in 2021 and in Brazil in 2022, for the treatment of chorea associated with Huntington’s disease and for the treatment of tardive dyskinesia. In February 2024, we announced a strategic partnership for the marketing and distribution of AUSTEDO in China with Jiangsu Nhwa Hexin Pharmaceutical Marketing Co., Ltd. In April 2025, AUSTEDO received marketing authorization in South Korea. We continue to evaluate additional submissions in various other markets. COPAXONE revenues in our International Markets segment in the first quarter of 2026 were $6 million a decrease of 43% compared to the first quarter of 2025. International Markets Gross Profit Gross profit from our International Markets segment in the first quarter of 2026 was $243 million, a decrease of 12% compared to the first quarter of 2025. Gross profit margin for our International Markets segment in the first quarter of 2026 decreased to 46.4%, compared to 47.7% in the first quarter of 2025. This decrease was mainly due to unfavorable mix of products, partially offset by a positive impact from hedging activities. International Markets Profit Profit from our International Markets segment consists of revenues less cost of sales, R&D expenses, S&M expenses, G&A expenses and other expenses (income) related to this segment. Segment profit does not include amortization and certain other items. Profit from our International Markets segment in the first quarter of 2026 was $65 million, a decrease of 33%, compared to the first quarter of 2025. This decrease was mainly due to lower gross profit, as discussed above. Other Activities We have other sources of revenues, primarily the sale of APIs to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through our affiliate Medis. Our other activities are not included in our United States, Europe or International Markets segments described above. In alignment with our Pivot to Growth strategy, commencing January 1, 2026, Anda is no longer reported under our United States segment. This shift allows the United States segment to continue to manage its entire product portfolio in the region, while strengthening focus on its biopharmaceutical business, growth engines and innovation. As a result, from that date, Anda is reported as part of the Company’s Other Activities. Prior period amounts were recast to reflect this change. Our revenues from other activities in the first quarter of 2026 were $584 million, an increase of 1% compared to the first quarter of 2025. In local currency terms, revenues decreased by 1% compared to the first quarter of 2025. Anda revenues from third-party products in the first quarter of 2026 were $378 million, an increase of 1%, compared to the first quarter of 2025. Anda, our distribution business in the United States operates independently and distributes generic and innovative medicines and OTC pharmaceutical products from various manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals and physician offices in the United States. Anda competes in the distribution market by maintaining a broad portfolio of products, competitive pricing and delivery throughout the United States. API sales to third parties in the first quarter of 2026 were $109 million, a decrease of 17% in both U.S. dollars and local currency terms, compared to the first quarter of 2025. This decrease was mainly due to price reductions and lower demand due to market dynamics. Revenues from additional other activities, mainly from Medis and certain contract manufacturing services, in the first quarter of 2026 were $97 million, an increase of 28% in U.S. dollars compared to the first quarter of 2025. In local currency terms, revenues increased by 16% compared to the first quarter of 2025, mainly due to higher demand. 2026 Financial Outlook $ billions, except diluted EPS or as noted Stand-Alone Outlook (Jan. 2026) Emalex April 2026 Revenues 16.4 - 16.8 16.4 - 16.8 AUSTEDO ($m) 2,400 - 2,550 2,400 - 2,550 AJOVY ($m) 750 - 790 750 - 790 UZEDY ($m) 250 - 280 250 - 280 Operating Income * 4.55 - 4.8 (0.77) 3.8 - 4.0 Adjusted EBITDA * 5.0 - 5.3 (0.77) 4.23 – 4.53 Finance Expenses* ($m) ~800 ~800 Tax Rate* 16% - 19% (+400 bps to ETR) 20% - 23% Diluted EPS* ($) 2.57 - 2.77 (0.66) 1.91 - 2.11 Free Cash Flow* 2.0 - 2.4 2.0 - 2.4 CAPEX 0.5 0.5 Foreign Exchange Volatile swings in FX can negatively impact revenue and income * Certain items above are non-GAAP financial measures. For more information, see “Non-GAAP Financial Measures” below. Free Cash Flow includes cash flow generated from operating activities net of capital expenditures and deferred purchase price cash component collected for securitized trade receivables. Conference Call Teva will host a conference call and live webcast along with a slide presentation on Wednesday, April 29, 2026 at 8:00 a.m. ET to discuss its first quarter 2026 financial results and overall business environment. A question & answer session will follow. In order to participate, please register in advance here to obtain a local or toll‐free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit . Some amounts in this press release may not add up due to rounding. All percentages have been calculated using unrounded amounts. Non-GAAP Financial Measures This press release contains certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures, including, but not limited to, non-GAAP operating income, non-GAAP operating margin, non-GAAP gross profit, non-GAAP gross profit margin, Adjusted EBITDA, free cash flow, non-GAAP tax rate, non-GAAP net income (loss) attributable to Teva and non-GAAP diluted EPS, are presented in order to facilitate investors' understanding of our business. We utilize certain non-GAAP financial measures to evaluate performance in conjunction with other performance metrics. The following are examples of how we utilize the non-GAAP measures: our management and board of directors use the non-GAAP measures to evaluate our operational performance and, to compare our results against work plans and budgets, and ultimately to evaluate the performance of management; our annual budgets are prepared on a non-GAAP basis; and senior management’s annual compensation is derived, in part, using these non-GAAP measures. See the attached tables for a reconciliation of the GAAP results to the adjusted non-GAAP measures. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP. We are not providing the most comparable forward-looking GAAP measures for non-GAAP metrics included in our financial outlook or a quantitative reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures because we are unable to predict with reasonable certainty the ultimate outcome of certain significant items including, but not limited to, the amortization of purchased intangible assets, legal settlements and loss contingencies, impairment of long-lived assets and goodwill impairment, without unreasonable effort. These items are uncertain, depend on various factors, and could be material to our results computed in accordance with GAAP. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies and changes in regulatory policy that may result in costs and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products in a timely manner; intense competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all; our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies, including the imposition of tariffs in the jurisdictions in which we operate, and any effects of such developments on sales of our products and the pricing and availability of raw materials; effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks, as well as risks and uncertainties related to the adoption of artificial intelligence technologies, and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting business globally, including political or economic instability, prolonged government shutdowns, widespread outbreaks of major diseases and major hostilities or acts of terrorism, ongoing global conflicts, including in the Middle East with the war involving Iran, and the war between Russia and Ukraine; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively consummate such sales and divestitures, including our planned divestiture of our API business; compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory requirements, the effects of regulatory uncertainty and changes and the results of increased regulatory oversight, including expenditures required to ensure compliance with research, production and quality control regulations and remedial actions taken to address product issues, such as delayed product launches, product recalls, and facility shutdowns; the effects of governmental, regulatory and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage, including as a result of the One Big Beautiful Bill signed into law in the U.S. in July 2025 (“OBBBA”), which will likely reduce the number of insured in Medicaid and Health Insurance Exchange markets, which may alter utilization patterns and shift negotiating leverage among payors, U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid by Americans for prescription medicines, including most-favored-nation pricing and related regulatory efforts; legal and regulatory actions in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan ® (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement (“DPA”) with the U.S. Department of Justice (“DOJ”); potential liability for intellectual property right infringement; significant product liability claims; claims brought by regulatory agencies; failure to comply with complex Medicare, Medicaid and other governmental programs’ reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks; and the impact of sustainability issues; other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; impairments of our long-lived assets; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; and the impact of any failure to maintain effective internal control over our financial reporting; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Consolidated Statements of Income (U.S. dollars in millions, except share and per share data) (Unaudited) Three months ended March 31, 2026 2025 Net revenues 3,982 3,891 Cost of sales 2,011 2,014 Gross profit 1,972 1,877 Research and development expenses 222 247 Selling and marketing expenses 696 622 General and administrative expenses 304 297 Intangible assets impairments 8 121 Other asset impairments, restructuring and other items.............. 26 (22) Legal settlements and loss contingencies...................... 72 86 Other loss (income) ................................................................... (9) 5 Operating income (loss) 652 519 Financial expenses, net 216 225 Income (loss) before income taxes 437 294 Income taxes (benefit).......................................................... 67 74 Share in (profits) losses of associated companies, net 1 § Net income (loss) 369 220 Net income (loss) attributable to redeemable and non-redeemable non-controlling interest § 6 Net income (loss) attributable to Teva 369 214 § Represents an amount less than $0.5 million. Earnings (loss) per share attributable to Teva: Basic ($) 0.32 0.19 Diluted ($) 0.31 0.18 Weighted average number of shares (in millions): Basic 1,156 1,138 Diluted 1,179 1,159 Non-GAAP net income attributable to Teva for diluted earnings per share:* 621 602 Non-GAAP earnings per share attributable to Teva:* Diluted ($) 0.53 0.52 Non-GAAP average number of shares (in millions): Diluted 1,179 1,159 Amounts may not add up due to rounding. § Represents an amount less than $0.5 million. * See reconciliation attached. CONSOLIDATED BALANCE SHEETS (U.S. dollars in millions, except for share data) (Unaudited) March 31, December 31, 2026 2025 ASSETS Current assets: Cash and cash equivalents $ 3,741 $ 3,556 Accounts receivables, net of allowance for credit losses of $75 million and $81 million as of March 31, 2026 and December 31, 2025, respectively. 3,393 3,709 Inventories 3,176 3,179 Prepaid expenses 1,070 1,122 Other current assets 535 539 Assets held for sale 1,794 1,842 Total current assets 13,710 13,946 Deferred income taxes 2,190 2,191 Other non-current assets 377 405 Property, plant and equipment, net 3,998 4,080 Operating lease right-of-use assets, net 335 345 Identifiable intangible assets, net 3,609 3,781 Goodwill 15,822 16,000 Total assets $ 40,040 $ 40,748 LIABILITIES AND EQUITY Current liabilities: Short-term debt $ 2,612 $ 1,820 Sales reserves and allowances 3,707 4,143 Accounts payables 2,596 2,531 Employee-related obligations 555 739 Accrued expenses 2,616 2,687 Other current liabilities 1,111 1,182 Liabilities held for sale 334 354 Total current liabilities 13,532 13,456 Long-term liabilities: Deferred income taxes 273 296 Other taxes and long-term liabilities 3,709 3,808 Senior notes and loans 14,015 14,986 Operating lease liabilities 280 288 Total long-term liabilities 18,277 19,379 Equity: Teva shareholders’ equity: 8,228 7,910 Non-controlling interests 4 4 Total equity 8,232 7,914 Total liabilities and equity $ 40,040 $ 40,748 Amounts may not add up due to rounding. TEVA PHARMACEUTICAL INDUSTRIES LIMITED CONSOLIDATED STATEMENTS OF CASH FLOWS (U.S. dollars in millions) (Unaudited) Three months ended March 31, 2026 2025 Operating activities: Net income (loss)........................................................................................... $ 369 220 Adjustments to reconcile net income (loss) to net cash provided by operations: Depreciation and amortization 239 244 Impairment of long-lived assets and assets held for sale 10 77 Net change in operating assets and liabilities (617) (700) Deferred income taxes – net and uncertain tax positions (22) 28 Stock-based compensation 43 34 Other items (54) (10) Net loss (gain) from sale of business and long-lived assets (8) 2 Net cash provided by (used in) operating activities (40) (105) Investing activities: Beneficial interest collected in exchange for securitized accounts receivables 354 322 Purchases of property, plant and equipment and intangible assets (168) (127) Proceeds from sale of business and long-lived assets, net 42 17 Purchases of investments and other assets . - (11) Other investing activities 1 - Net cash provided by (used in) investing activities 229 201 Financing activities: Repayment of senior notes and loans and other long-term liabilities - (1,368) Repayment of convertible debentures (23) - Purchase of shares from redeemable and non-redeemable non-controlling interests - (38) Dividends paid to redeemable and non-redeemable non-controlling interests - (340) Other financing activities 36 3 Net cash provided by (used in) financing activities 13 (1,744) Effect of exchange rate changes on cash and cash equivalents (17) 45 Net change in cash and cash equivalents 185 (1,603) Balance of cash and cash equivalents at beginning of period 3,556 3,300 Balance of cash and cash equivalents at end of period $ 3,741 1,697 Non-cash financing and investing activities: Beneficial interest obtained in exchange for securitized accounts receivables $ 311 311 Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva (Unaudited) Three months ended March 31, ($ in millions except per share amounts) 2026 2025 Net income (loss) attributable to Teva $ 369 214 Increase (decrease) for excluded items: Amortization of purchased intangible assets 137 145 Legal settlements and loss contingencies (1) 72 83 Impairment of long-lived assets 9 77 Restructuring costs 25 14 Equity compensation 43 34 Contingent consideration 5 11 Loss (gain) on sale of business (5) 7 Financial expenses 13 14 Other non-GAAP items (2) 17 57 Corresponding tax effects and unusual tax items (3) (65) (55) Non-GAAP net income attributable to Teva $ 621 602 Non-GAAP tax rate (4) 17.5% 17.5% GAAP diluted earnings (loss) per share attributable to Teva $ 0.31 0.18 EPS difference (5) 0.21 0.33 Non-GAAP diluted EPS attributable to Teva (5) $ 0.53 0.52 Non-GAAP average number of shares (in millions) (5) 1,179 1,159 (1) For the three months ended March 31, 2026 and 2025, adjustments for legal settlements and loss contingencies primarily consisted of $48 million and $50 million, respectively, related to the provision for the opioid cases (mainly the effect of the passage of time on the net present value of the discounted payments). (2) Other non-GAAP items include other exceptional items that we believe are sufficiently large that their exclusion is important to facilitate an understanding of trends in our financial results, primarily related to the rationalization of our plants, accelerated depreciation, material litigation fees and other unusual events. (3) For the three months ended March 31, 2026 and 2025, adjustments for corresponding tax effects and unusual tax items exclusively consisted of the tax impact directly attributable to the pre-tax items that are excluded from non-GAAP net income included in the other adjustments to this table. (4) Non-GAAP tax rate is tax expenses (benefit) excluding the impact of non-GAAP tax adjustments presented above as a percentage of income (loss) before income taxes excluding the impact of non-GAAP adjustments presented above. (5) EPS difference and diluted non-GAAP EPS are calculated by dividing our non-GAAP net income attributable to Teva by our non-GAAP diluted weighted average number of shares. Reconciliation of gross profit to Non-GAAP gross profit (Unaudited) Three months ended March 31, ($ in millions) 2026 2025 Gross profit $ 1,972 1,877 Gross profit margin 49.5% 48.2% Increase (decrease) for excluded items: (1) Amortization of purchased intangible assets 128 135 Equity compensation 6 6 Other non-GAAP items 3 37 Non-GAAP gross profit $ 2,108 2,054 Non-GAAP gross profit margin (2) 52.9% 52.8% (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. (2) Non-GAAP gross profit margin is non-GAAP gross profit as a percentage of revenue. Reconciliation of operating income (loss) to Non-GAAP operating income (loss) (Unaudited) Three months ended March 31, ($ in millions) 2026 2025 Operating income (loss) $ 652 519 Operating margin 16.4% 13.3% Increase (decrease) for excluded items: (1) Amortization of purchased intangible assets 137 145 Legal settlements and loss contingencies 72 83 Impairment of long-lived assets 9 77 Restructuring costs 25 14 Equity compensation 43 34 Contingent consideration 5 11 Loss (gain) on sale of business (5) 7 Other non-GAAP items 17 56 Non-GAAP operating income (loss) $ 956 946 Non-GAAP operating margin (2) $ 24.0% 24.3% (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. (2) Non-GAAP operating margin is Non-GAAP operating income as a percentage of revenues. Reconciliation of net income (loss) to adjusted EBITDA (Unaudited) Three months ended March 31, ($ in millions) 2026 2025 Net income (loss) $ 369 220 Increase (decrease) for excluded items: (1) Financial expenses 216 225 Income taxes 67 74 Share in profits (losses) of associated companies –net 1 § Depreciation 102 99 Amortization 137 145 EBITDA 892 763 Legal settlements and loss contingencies 72 83 Impairment of long lived assets 9 77 Restructuring costs 25 14 Equity compensation 43 34 Contingent consideration 5 11 Loss (Gain) on sale of Business (5) 7 Other non-GAAP items 15 52 Adjusted EBITDA $ 1,055 1,041 (1) For further explanations, refer to the footnotes under the "Reconciliation of net income (loss) attributable to Teva to Non-GAAP net income (loss) attributable to Teva" table. § Represents an amount of less than $0.5 million. Segment Information (Unaudited) United States Europe International Markets Three months ended March 31, Three months ended March 31, Three months ended March 31, 2026 2025 2026 2025 2026 2025 (U.S. $ in millions) (U.S. $ in millions) (U.S. $ in millions) Revenues $ 1,534 $ 1,536 $ 1,340 $ 1,194 $ 524 $ 582 Cost of sales 496 523 606 536 280 304 Gross profit 1,038 - 1,013 - 734 - 658 - 243 - 278 R&D expenses 147 154 45 60 22 25 S&M expenses 298 244 215 199 117 118 G&A expenses 90 95 73 69 39 39 Other (4) 3 § § § (1) Segment profit* $ 507 $ 518 $ 401 $ 329 $ 65 $ 97 * Segment profit does not include amortization and certain other items. § Represents an amount less than $0.5 million. Reconciliation of our segment profit to consolidated income (loss) before income taxes Three months ended March 31, 2026 2025 (U.S.$ in millions) United States profit $ 507 $ 518 Europe profit 401 329 International Markets profit 65 97 Total reportable segment profit 972 944 Profit (loss) of other activities (16) 2 Amounts not allocated to segments: Amortization 137 145 Other asset impairments, restructuring and other items 26 (22) Intangible asset impairments 8 121 Legal settlements and loss contingencies 72 83 Other unallocated amounts 60 99 Consolidated operating income (loss) 652 519 Financial expenses - net 216 225 Consolidated income (loss) before income taxes $ 437 $ 294 Segment revenues by major products and activities (Unaudited) Three months ended Percentage March 31, Change 2026 2025 2026-2025 (U.S.$ in millions) United States segment Generic products (including biosimilars) $ 612 $ 849 (28%) AJOVY 87 53 64% AUSTEDO 559 396 41% BENDEKA and TREANDA 27 36 (26%) COPAXONE 62 54 16% UZEDY 63 39 62% Other* 123 109 13% Total 1,534 1,536 § *Other revenues in the first quarter of 2026 include the sale of certain product rights. § Represents an amount less than 0.5%. Three months ended Percentage March 31, Change 2026 2025 2026-2025 (U.S.$ in millions) Europe segment Generic products (including OTC and biosimilars) $ 1,089 $ 989 10% AJOVY 76 58 31% COPAXONE 40 42 (4%) Respiratory products 59 55 8% Other* 76 50 52% Total 1,340 1,194 12% *Other revenues in the first quarter of 2026 and 2025 include the sale of certain product rights. Three months ended Percentage March 31, Change 2026 2025 2026-2025 (U.S.$ in millions) International Markets segment Generic products (including OTC and biosimilars) $ 386 $ 468 (18%) AJOVY 33 28 20% AUSTEDO 19 15 30% COPAXONE 6 10 (43%) Other* 79 61 30% Total 524 582 (10%) *Other revenues in the first quarter of 2026 and 2025 include the sale of certain product rights. Free cash flow reconciliation (Unaudited) Three months ended March 31, 2026 2025 (U.S. $ in millions) Net cash provided by (used in) operating activities (40) (105) Beneficial interest collected in exchange for securitized account receivables 354 322 Capital investment (168) (127) Proceeds from divestitures of businesses and other assets, net 42 17 Free cash flow $ 188 $ 107 Net debt reconciliation unaudited March 31, 2026 Short-term debt 2,612 Senior notes and loans 14,015 Total debt 16,627 Net of cash and cash equivalents 3,741 Net debt $ 12,886 Teva Media Inquiries TevaCommunicationsNorthAmerica@tevapharm.com Teva Investor Relations Inquiries TevaIR@Tevapharm.com

Clinical ResultNDADrug ApprovalAcquisitionPhase 3

16 Apr 2026

·www.globenewswire.com

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) at AAN 2026

Poster scheduled for presentation on Tuesday, April 21, 8:00 AM - 9:00 AM CDTNESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present efficacy data from GA Depot clinical studies in patients with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) at the American Academy of Neurology (AAN) Annual Meeting 2026, to take place April 18-22, 2026, in Chicago IL. Mapi’s Glatiramer Acetate Depot (GA Depot) is a long-acting injection version of the approved Glatiramer Acetate (GA, commercially available as Copaxone®) for treating multiple sclerosis (MS), a chronic inflammatory, demyelinating disease characterized by neurological disability accumulation over time. GA Depot was clinically evaluated for RMS which is characterized by inflammatory attacks (relapses) on the central nervous system, causing new or worsening neurological symptoms followed by partial or full recovery and PPMS which is characterized by continued worsening neurologic function from the onset of symptoms, without early relapses or remissions. EDSS (Expanded Disability Status Scale) assessments were collected from two prospective GA Depot clinical studies: an up to three year, open-label, Phase IIa study in PPMS patients (n=30), and a one-year, double-blind, placebo-controlled, pivotal Phase III study in RMS patients (n=1,016 of which n=508 were in the active arm). GA Depot is administered intramuscularly (IM) once every 28 days for both indications at different dosages. In the above studies in PPMS and RMS, GA Depot showed EDSS stabilization, irrespective of baseline EDSS scores. These EDSS findings suggest GA Depot’s potential in slowing disability progression, reinforcing its role in MS management. GA Depot is in a final review process in Germany for the RMS indication and is planned to start a global Phase III study for PPMS. Mapi received the Israeli Ministry of Health’s GMP (Good Manufacturing Practice) approval, enabling commercial launch in RMS in 2027 in Germany and in EU countries and initiation of marketing early 2028. Ehud Marom, Chairman and Chief Executive Officer, Mapi Pharma, said, “We are very excited to share these positive results for GA Depot in the treatment of MS, where there are significant unmet medical needs. The data we are presenting this week at AAN demonstrate that GA Depot can significantly impact disease progression and we believe that this product, once approved, has the potential to transform the treatment landscape for MS. We look forward to further evaluating GA Depot in the clinic in the PPMS indication and are currently seeking a co-marketing partner for GA Depot for the RMS indication in the EU.” The GA Depot data will be featured in a poster GA Depot (long-acting IM glatiramer acetate) and its impact on EDSS in Relapsing forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) on Tuesday, April 21, 8:00 AM - 9:00 AM CDT (Poster Neighborhood 19 P7: Multiple Sclerosis: Clinical Trials 1, McCormick Place West, Hall F). Company management will be available for one-on-one meetings during the conference to discuss potential joint development collaborations. Interested parties should contact Mapi directly. About Mapi Pharma Mapi Pharma (Mapi) is a clinical stage pharmaceutical company, engaged in development of high barrier-to-entry and high added-value life cycle management ("LCM") products and AB Rated Depot injectable products that target large markets that include complex active pharmaceutical ingredients ("APIs") and formulations. Mapi is developing depot long-acting injections for the anti-psychotic Cariprazine and for the GLP-1’s, Semaglutide and Tirzepatide for diabetes and weight management as well as a generic AB rated version for Naltrexone (Vivitrol®). The Company is also marketing its own generic versions of Fingolimod (Gilenya®) and Apremilast (Otezla®) in specific geographic markets. Mapi is built on strong chemical and pharmaceutical R&D and clinical development capabilities and a deep understanding of the global market and of regulatory needs. Mapi is a global company with a dedicated long-acting depot R&D laboratory and aseptic depot manufacturing and a Fill & Finish for injectable Finished Dosage Forms. Mapi has strong IP positions, numerous granted patent applications for APIs and mainly formulations. For more information, please visit www.mapi-pharma.com Contacts: Alex MogleVice President, Corporate DevelopmentMapi Pharma+972 52 6080297alex@mapi-pharma.com Brian RitchieManaging DirectorLifeSci Advisors, LLCbritchie@lifesciadvisors.com

Clinical ResultPhase 2Phase 3

100 Deals associated with Glatiramer Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D04318	Glatiramer Acetate	L03AX13	DB05259

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis	United States	Teva Pharmaceuticals USA, Inc.	28 Jan 2014
Multiple Sclerosis, Relapsing-Remitting	United States	Teva Pharmaceuticals USA, Inc.	20 Dec 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple sclerosis relapse	Phase 3	United States	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Belarus	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Bosnia and Herzegovina	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Bulgaria	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Estonia	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Israel	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Moldova	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Russia	Mapi-Pharma Ltd.	19 Sep 2019
Multiple sclerosis relapse	Phase 3	Ukraine	Mapi-Pharma Ltd.	19 Sep 2019
Rhabdomyosarcoma	Phase 3	United States	Mapi-Pharma Ltd.	19 Sep 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ACTRIMS2026	Phase 2	Multiple Sclerosis, Primary Progressive	30	Glatiramer Acetate Depot 25 mg	uygigqargq(brtgfhlhpw) = bzgtviokam ocqleiserp (wdbwenmvyg ) View more	Positive	05 Feb 2026
				Glatiramer Acetate Depot 40 mg	cbmfzixidl(hpetptxxzp) = yubmchqivr tfpvtopoqa (zsgeyihrlu ) View more
P8-6.018 (AAN2024)	Phase 3	Multiple sclerosis relapse	-	GA Depot	soevktvkzh(cpacrexqyx) = etfvekgrck drsinmhkqn (dupsbbbunk ) View more	Positive	09 Apr 2024
				Copaxone	soevktvkzh(cpacrexqyx) = dofpvrqdxb drsinmhkqn (dupsbbbunk ) View more
S31.010 (AAN2024)	Not Applicable	Multiple Sclerosis	930	Fingolimod	woifmzjvtu(fgllutpfye) = njvcbbjjvw hmxhtxwsfw (diezmdnxpv )	Negative	09 Apr 2024
				Natalizumab	woifmzjvtu(fgllutpfye) = gyttwagtre hmxhtxwsfw (diezmdnxpv )
GA Depot, Phase 3 (ACTRIMS2024)	Phase 3	Multiple sclerosis relapse	763	GA Depot	nifwaknlxy(ccditwnpze) = mean percent change 8.34 rrvdkcymts (kynojhbwow )	Positive	29 Feb 2024
Phase III Open Label period (ACTRIMS2024)	Phase 3	-	821	Glatiramer Acetate Depot	vxsgqgqdxz(ioimhsnkpw) = The most frequent TEAEs reported (≥5% of the subjects in any treatment group), irrespective of the relatedness, were ISRs, pyrexia, influenza-like illness, body temperature increase, and headache jijvakpckg (euyebwtkum ) View more	Positive	29 Feb 2024
				Placebo
NCT04121221 (ECTRIMS2023)	Phase 3	Multiple sclerosis relapse	-	GA Depot	yysxdhzesg(iahgvppppf) = fdhhwnkvdu vewiknwtfm (zbibrivrel ) View more	-	30 Sep 2023
				Copaxone®	yysxdhzesg(iahgvppppf) = ggpkfjmfen vewiknwtfm (zbibrivrel ) View more
AAN2022	Phase 2	Multiple Sclerosis, Relapsing-Remitting anti-GA antibodies	-	GA Depot 80mg	ntyttowvxb(kjbhjmwpuw) = jpyetntfcm lhbngnfelq (nprccfgopw, +/ - 1.13) View more	Positive	03 May 2022
				GA Depot 40mg	ntyttowvxb(kjbhjmwpuw) = qojkkszxfw lhbngnfelq (nprccfgopw, +/ - 1.25) View more
NCT00176592 (BECOME, CTgov)	Phase 4	Multiple Sclerosis \| Multiple Sclerosis, Relapsing-Remitting	75	Betaseron (Betaseron)	qydrbfqvxn(rjhdwcxufq) = vtufnifdws oqmfqyuoxq (bitjimmohg, 2.76) View more	-	16 Nov 2021
				Copaxone (Copaxone)	qydrbfqvxn(rjhdwcxufq) = riuephlake oqmfqyuoxq (bitjimmohg, 2.46) View more
NCT00326625 (CTgov)	Phase 2	Amyotrophic Lateral Sclerosis	366	Placebo	zmfxoehymp(afgndnaykc) = tmkzdxnkds vifjzmfzfj (tsrqspyzlh, 0.058) View more	-	20 Oct 2021
GA Depot phase IIa (ECTRIMS 12020 \| ECTRIMS 22020 \| AAN2020)	Phase 2	Multiple Sclerosis, Primary Progressive	11	GA Depot	uhjlasdqvz(kdzdpzqcde) = stable hlzglfnnot (wzciwinjpq ) View more	Positive	07 Dec 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis